Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors

by admin | June 9, 2026 | Latest news, Press Releases

Copenhagen, Denmark, 09 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces the election of Keith Leonard as Chairman of its Board of Directors. Keith is a...

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

by admin | June 7, 2026 | Latest news, Press Releases

AT7687 demonstrated a favorable safety and tolerability profile with no adverse GI tolerability signals identified Once-weekly dosing potential and demonstrated target engagement across the doses tested were confirmed Preclinical data from non-human primates showed...

Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer

by admin | May 21, 2026 | Latest news, Press Releases

Copenhagen, Denmark, 21 May 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces the appointment of Philip Just Larsen MD, PhD as Chief Executive Officer (CEO)....

Antag Therapeutics to present data on AT7687, its first-in-class GIPR antagonist peptide at the American Diabetes Association’s 2026 Scientific Sessions

by admin | April 23, 2026 | Latest news, Press Releases

Copenhagen, Denmark, 23 April 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces that it will deliver an oral presentation at the 2026 Scientific Sessions of the...

Antag Therapeutics demonstrates compelling potential of its novel GIPR antagonist for obesity, reporting excellent tolerability in Phase 1 and enhanced weight loss in amylin combination study

by admin | January 8, 2026 | Latest news, Press Releases

Copenhagen, Denmark, 8 January 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces topline data from two studies evaluating AT7687, its first-in-class GIPR...

Antag Therapeutics expands senior team to support clinical progress

by admin | April 23, 2025 | Latest news, Press Releases

Antag Therapeutics (“Antag” or “the Company”), a biopharmaceutical company pioneering novel treatments for obesity, today announces the appointment of three new hires to support the Company’s next phase of growth following the recent initiation of a Phase 1 trial of...